UNSPSC 51263102: Arotinolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H21N3O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 394E3P3B99, chemically known as 5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide but generally known as arotinolol, which bears US NIH Compound Identifier 2239. Arotinolol most often comes in base and hydrochloride forms.

UNSPSC 51263102 Arotinolol is a Commodity code that does not align with recent state and local procurement activity in the available record. The single opportunity tagged under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems for community health initiatives, a scope that falls outside the pharmaceutical ingredient classification implied by the code's name. The mismatch suggests either miscoding at the issuing body or a data-quality issue in the taxonomic assignment.

Seminole County posted the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023 (a date inconsistency in the source itself), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries an initial two-year term with one-year renewal option, and compliance requirements include drug-free workplace certification, E-Verify authorization, and federal compliance obligations under FEMA funding. The procurement shows no explicit set-aside or disadvantaged-enterprise designation. Without additional recent opportunities correctly coded to this Commodity, current market activity under UNSPSC 51263102 remains unclear.